KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Researchers want to learn if using a study medicine called MK-1084 can help treat Non-Small Cell Lung Cancer (NSCLC). MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this study is to learn about the safety of MK-1084 and to learn how many people have the cancer get smaller or go away during the study treatment.

NCT Number	NCT07252739
Lead Sponsor	Merck Sharp & Dohme LLC
Conditions	Malignant Neoplasm
Enrollment	140 participants
Start Date	2025-12-19
Primary Completion	2033-01-14 (estimated)
Study Completion	2033-01-14 (estimated)
Updated on ClinicalTrials.gov	2026-07-30